CORONA, Calif., and MIAMI and SIOUX FALLS, S.D., May 14, 2020 — RESTEM, a leading cell-based therapeutics company, announced today it has received approval from the U.S. Food and Drug Administration (FDA) for a 60-patient Phase I/IIa study using umbilical cord mesenchymal stem cells to treat patients with severe cases of COVID-19. The study will be the first of its kind in the U.S. “We are […]
A single mom in Florida’s sweet reunion with her two children was captured on video more than three weeks after she was first admitted to the hospital to be treated for coronavirus. Ruthie Ramirez tested positive for COVID-19 on April 7, and was admitted to the intensive care unit and placed on a ventilator, WFOR reported. For […]
MIAMI (CBSMiami) – The U.S. Food and Drug Administration gave Baptist Health approval to test a stem cell treatment on COVID-19 patients and so far it’s come back with positive results. The treatment has proven successful with three patients. One of those patients, Ruth Ramirez says it saved her life. Ramirez was discharged from the hospital on Friday afternoon. […]
RESTEM, a leading-edge biotechnology company, and Baptist Health South Florida, today announced three COVID-19 patients with acute respiratory distress syndrome (ARDS) are the first to successfully be treated in the U.S. with umbilical cord mesenchymal stem cells under an emergency approval from the Food and Drug Administration (FDA). Baptist Health physicians, Guenther Koehne, M.D., Ph.D., and Javier […]
A team of South Florida doctors have successfully treated three critically ill COVID-19 patients with an experimental stem cell treatment for the first time, signaling a potential path to recovery for patients experiencing acute respiratory failure. The doctors at Baptist Health South Florida, say the intravenous treatment is a “game-changer” and could pave the way for an […]
RESTEM to donate its proprietary ULSCs in an approved investigational new drug application phase I clinical study at University of Florida on Polymyositis/Dermatomyositis entitled, “LEVERAGING THE IMMUNOMODULATORY CAPACITY OF MESENCHYMAL STROMAL CELLS FOR THE THERAPY OF REFRACTORY POLYMYOSITIS AND DERMATOMYOSITIS”.
University of Murcia, Spain commences preclinical umbilical cord lining stem cells (ULSCs) animal work on safety, toxicity and biodistribution. University of Murcia will look at safety and toxicity inin vivo animal models. Moreover, they will use a tracking system on the cells to identify where cells travel to following an intravenous infusion in vivo.
University of Murcia, Spain completes preclinical umbilical cord lining stem cells (ULSCs) animal work illustrating safety and no toxic affects following infusion of ULSCs. Moreover, biodistribution clearly illustrates location and migration of ULSCs in animal models.
RESTEM acquires umbilical cord lining stem cells (ULSCs) technology rights in full to include all intellectual property of such, previous studies and any/all research & development previously completed on ULSCs.